Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2018 08:00 ET | Source: Cellectar Biosciences, Inc.

Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers

MADISON, Wis., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
January 22, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference

MADISON, Wis., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
January 04, 2018 08:00 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Participate at Biotech Showcase 2018

MADISON, Wis., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
December 14, 2017 08:43 ET | Source: Cellectar Biosciences, Inc.

Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers

MADISON, Wis., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
December 06, 2017 08:00 ET | Source: Cellectar Biosciences, Inc.

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131

MADISON, Wis., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
November 20, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 10th Annual LD Micro Main Event

Madison, Wis., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
November 09, 2017 16:01 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance

MADISON, Wis., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today reported financial...
November 07, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma

MADISON, Wis., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that the...
November 02, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance

MADISON, Wis., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that...
October 30, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation

MADISON, Wis., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces data...